

Appl. No. 10/081,974
Amtd. dated September 1, 2004
Reply to Office Action of June 29, 2004

Amendments to the Claims

1. (Currently Amended) A method for treating cancer in a cancer patient with p53 mutation comprising:

administering 5-fluorouracil to the patient; and

administering to the cancer patient a water-insoluble 20(S)-camptothecin 9-nitro-20(S)-camptothecin or 9-amino-20(S)-camptothecin at least 1 day before or after administering 5-fluorouracil to the patient for a period of time during which and when 5-fluorouracil is not being administered to the patient and is not present in a pharmaceutically active form in the patient; and

administering 5-fluorouracil to the patient, wherein the period of time during which 5-fluorouracil is not being administered to the patient is at least 1 day, and the water insoluble 20(S)-camptothecin is 9-nitro-20(S)-camptothecin or 9-amino-20(S)-camptothecin.

2. (Currently Amended) A method according to claim 1 wherein the 20(S)-camptothecin 9-nitro-20(S)-camptothecin or 9-amino-20(S)-camptothecin is administered at least 1 day before 5-fluorouracil is administered.

3. (Currently Amended) A method according to claim 1 wherein the 20(S)-camptothecin 9-nitro-20(S)-camptothecin or 9-amino-20(S)-camptothecin is administered at least 2 days before 5-fluorouracil is administered.

4. (Currently Amended) A method according to claim 1 wherein the 20(S)-camptothecin 9-nitro-20(S)-camptothecin or 9-amino-20(S)-camptothecin is administered at least 3 days before 5-fluorouracil is administered.

5. (Currently Amended) A method according to claim 1 wherein the 20(S)-camptothecin 9-nitro-20(S)-camptothecin or 9-amino-20(S)-camptothecin is administered at least 4 days before 5-fluorouracil is administered.

6. (Currently Amended) A method according to claim 1 wherein the 20(S)-camptothecin 9-nitro-20(S)-camptothecin or 9-amino-20(S)-camptothecin is administered at least 5 days before 5-fluorouracil is administered.

Appl. No. 10/081,974
Amdt. dated September 1, 2004
Reply to Office Action of June 29, 2004

7. (Currently Amended) A method according to claim 1 wherein ~~the 20(S)-camptothecin~~ 9-nitro-20(S)-camptothecin or 9-amino-20(S)-camptothecin is administered between 1 and 90 days before 5-fluorouracil is administered.

8. (Currently Amended) A method according to claim 1 wherein ~~the 20(S)-camptothecin~~ 9-nitro-20(S)-camptothecin or 9-amino-20(S)-camptothecin is administered between 2 and 90 days before 5-fluorouracil is administered.

9. (Currently Amended) A method according to claim 1 wherein ~~the 20(S)-camptothecin~~ 9-nitro-20(S)-camptothecin or 9-amino-20(S)-camptothecin is administered between 3 and 90 days before 5-fluorouracil is administered.

10. (Currently Amended) A method according to claim 1 wherein ~~the 20(S)-camptothecin~~ 9-nitro-20(S)-camptothecin or 9-amino-20(S)-camptothecin is administered between 4 and 90 days before 5-fluorouracil is administered.

11. (Currently Amended) A method according to claim 1 wherein ~~the 20(S)-camptothecin~~ 9-nitro-20(S)-camptothecin or 9-amino-20(S)-camptothecin camptothecin is administered between 5 and 90 days before 5-fluorouracil is administered.

12. (Currently Amended) A method according to claim 1 wherein ~~the 20(S)-camptothecin~~ 9-nitro-20(S)-camptothecin or 9-amino-20(S)-camptothecin is administered at least 1 day after 5-fluorouracil is administered.

13. (Currently Amended) A method according to claim 1 wherein ~~the 20(S)-camptothecin~~ 9-nitro-20(S)-camptothecin or 9-amino-20(S)-camptothecin is administered at least 2 days after 5-fluorouracil is administered.

14. (Currently Amended) A method according to claim 1 wherein ~~the 20(S)-camptothecin~~ 9-nitro-20(S)-camptothecin or 9-amino-20(S)-camptothecin is administered at least 3 days after 5-fluorouracil is administered.

Appl. No. 10/081,974
Amdt. dated September 1, 2004
Reply to Office Action of June 29, 2004

15. (Currently Amended) A method according to claim 1 wherein ~~the 20(S)-camptothecin~~ 9-nitro-20(S)-camptothecin or 9-amino-20(S)-camptothecin is administered at least 4 days after 5-fluorouracil is administered.
16. (Currently Amended) A method according to claim 1 wherein ~~the 20(S)-camptothecin~~ 9-nitro-20(S)-camptothecin or 9-amino-20(S)-camptothecin is administered at least 5 days after 5-fluorouracil is administered.
17. (Canceled)
18. (Currently Amended) A method according to claim 1 wherein ~~the 20(S)-camptothecin~~ 9-nitro-20(S)-camptothecin or 9-amino-20(S)-camptothecin is administered between 2 and 90 days before or after 5-fluorouracil is administered and is also administered within 2 days of when 5-fluorouracil is administered.
19. (Currently Amended) A method according to claim 1 wherein ~~the 20(S)-camptothecin~~ 9-nitro-20(S)-camptothecin or 9-amino-20(S)-camptothecin is administered between 3 and 90 days before or after 5-fluorouracil is administered and is also administered within 3 days of when 5-fluorouracil is administered.
20. (Currently Amended) A method according to claim 1 wherein ~~the 20(S)-camptothecin~~ 9-nitro-20(S)-camptothecin or 9-amino-20(S)-camptothecin is administered between 4 and 90 days before or after 5-fluorouracil is administered and is also administered within 4 days of when 5-fluorouracil is administered.
21. (Previously Presented) A method according to claim 1 wherein the patient has pancreatic cancer.
- 22-24. (Canceled)

Appl. No. 10/081,974
Amdt. dated September 1, 2004
Reply to Office Action of June 29, 2004

25. (Previously Presented) A method according to claim 1 wherein the patient has cancer selected from the group consisting of acute myelogenous leukemia, cholangiocarcinoma, chronic myelogenous leukemia, lymphoma, melanoma, multiple myeloma, osteosarcoma, gastric sarcoma, glioma, bladder, breast, cervical, colorectal, lung, ovarian, pancreatic, prostate, and stomach cancer.

26-53. (Canceled)